While changes of CgA levels in individual patients can be useful as surrogate for tumor progression, the levels do not reflect the aggressiveness of the tumor and further most aggressive G3 tumors often express less CgA compared to well differentiated tumors (Campana et al. 2007; Marotta et al. 2012). The gene discussed is CGA; the disease is neoplasm.